Valsartan effects on platelet activity in patients with arterial hypertension and metabolic syndrom

То assess angiotensin II receptor blocker effects on platelet aggregation in arterial hypertension (AH) and metabolic syndrome (MS), 34 patients were administered valsartanfor 16 weeks. The dynamics of anthropometry parameters, blood lipids, plasma and platelet lipid peroxidation, blood and blood ce...

Full description

Saved in:
Bibliographic Details
Main Authors: I. N. Medvedev, T. A. Kumova
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC 2007-06-01
Series:Российский кардиологический журнал
Subjects:
Online Access:https://russjcardiol.elpub.ru/jour/article/view/2154
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850026952048508928
author I. N. Medvedev
T. A. Kumova
author_facet I. N. Medvedev
T. A. Kumova
author_sort I. N. Medvedev
collection DOAJ
description То assess angiotensin II receptor blocker effects on platelet aggregation in arterial hypertension (AH) and metabolic syndrome (MS), 34 patients were administered valsartanfor 16 weeks. The dynamics of anthropometry parameters, blood lipids, plasma and platelet lipid peroxidation, blood and blood cell antioxidant potential, as well as platelet aggregation was investigated. Statistical analysis included Student and systemic multi-factor analysis methods. In AH and MS patients, valsartan improved peroxidation syndrome and platelet aggregation. For weight reduction, valsartan should be combined with non-pharmaceutical methods.
format Article
id doaj-art-530619bf0e5145ef830ab2bce055315b
institution DOAJ
issn 1560-4071
2618-7620
language Russian
publishDate 2007-06-01
publisher «FIRMA «SILICEA» LLC
record_format Article
series Российский кардиологический журнал
spelling doaj-art-530619bf0e5145ef830ab2bce055315b2025-08-20T03:00:22Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202007-06-010366691906Valsartan effects on platelet activity in patients with arterial hypertension and metabolic syndromI. N. Medvedev0T. A. Kumova1Курский институт социального образования – филиал Российского государственного социального университетаКурский институт социального образования – филиал Российского государственного социального университетаТо assess angiotensin II receptor blocker effects on platelet aggregation in arterial hypertension (AH) and metabolic syndrome (MS), 34 patients were administered valsartanfor 16 weeks. The dynamics of anthropometry parameters, blood lipids, plasma and platelet lipid peroxidation, blood and blood cell antioxidant potential, as well as platelet aggregation was investigated. Statistical analysis included Student and systemic multi-factor analysis methods. In AH and MS patients, valsartan improved peroxidation syndrome and platelet aggregation. For weight reduction, valsartan should be combined with non-pharmaceutical methods.https://russjcardiol.elpub.ru/jour/article/view/2154arterial hypertensionmetabolic syndromeplateletsvalsartan
spellingShingle I. N. Medvedev
T. A. Kumova
Valsartan effects on platelet activity in patients with arterial hypertension and metabolic syndrom
Российский кардиологический журнал
arterial hypertension
metabolic syndrome
platelets
valsartan
title Valsartan effects on platelet activity in patients with arterial hypertension and metabolic syndrom
title_full Valsartan effects on platelet activity in patients with arterial hypertension and metabolic syndrom
title_fullStr Valsartan effects on platelet activity in patients with arterial hypertension and metabolic syndrom
title_full_unstemmed Valsartan effects on platelet activity in patients with arterial hypertension and metabolic syndrom
title_short Valsartan effects on platelet activity in patients with arterial hypertension and metabolic syndrom
title_sort valsartan effects on platelet activity in patients with arterial hypertension and metabolic syndrom
topic arterial hypertension
metabolic syndrome
platelets
valsartan
url https://russjcardiol.elpub.ru/jour/article/view/2154
work_keys_str_mv AT inmedvedev valsartaneffectsonplateletactivityinpatientswitharterialhypertensionandmetabolicsyndrom
AT takumova valsartaneffectsonplateletactivityinpatientswitharterialhypertensionandmetabolicsyndrom